Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Gains from Sales and Divestitures (2016 - 2025)

Historic Gains from Sales and Divestitures for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Q3 2025 value amounting to $67000.0.

  • Lineage Cell Therapeutics' Gains from Sales and Divestitures changed 0.0% to $67000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $67000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $67000.0 for FY2024, which is 1625.0% down from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Gains from Sales and Divestitures stood at $67000.0 for Q3 2025, which was down 0.0% from $67000.0 recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Gains from Sales and Divestitures peaked at $80000.0 during Q1 2023, and registered a low of $16000.0 during Q1 2021.
  • In the last 5 years, Lineage Cell Therapeutics' Gains from Sales and Divestitures had a median value of $67000.0 in 2024 and averaged $55473.7.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Gains from Sales and Divestitures tumbled by 5000.0% in 2022, and later soared by 40000.0% in 2023.
  • Quarter analysis of 5 years shows Lineage Cell Therapeutics' Gains from Sales and Divestitures stood at $62000.0 in 2021, then crashed by 50.0% to $31000.0 in 2022, then surged by 158.06% to $80000.0 in 2023, then fell by 16.25% to $67000.0 in 2024, then changed by 0.0% to $67000.0 in 2025.
  • Its last three reported values are $67000.0 in Q3 2025, $67000.0 for Q2 2025, and $67000.0 during Q1 2025.